HRP20110045T1 - Sinteza acilaminoalkenilen amida korisnih kao antagonista supstance p - Google Patents

Sinteza acilaminoalkenilen amida korisnih kao antagonista supstance p Download PDF

Info

Publication number
HRP20110045T1
HRP20110045T1 HR20110045T HRP20110045T HRP20110045T1 HR P20110045 T1 HRP20110045 T1 HR P20110045T1 HR 20110045 T HR20110045 T HR 20110045T HR P20110045 T HRP20110045 T HR P20110045T HR P20110045 T1 HRP20110045 T1 HR P20110045T1
Authority
HR
Croatia
Prior art keywords
formula
compound
protecting group
boc protecting
image
Prior art date
Application number
HR20110045T
Other languages
English (en)
Croatian (hr)
Inventor
Portmann Robert
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0607532A external-priority patent/GB0607532D0/en
Priority claimed from GB0610244A external-priority patent/GB0610244D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20110045T1 publication Critical patent/HRP20110045T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20110045T 2006-04-13 2007-04-11 Sinteza acilaminoalkenilen amida korisnih kao antagonista supstance p HRP20110045T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0607532A GB0607532D0 (en) 2006-04-13 2006-04-13 Organic compounds
GB0610244A GB0610244D0 (en) 2006-05-23 2006-05-23 Organic compounds
PCT/EP2007/003213 WO2007118651A1 (en) 2006-04-13 2007-04-11 Synthesis of acylaminoalkenylene amides useful as substance p antagonists

Publications (1)

Publication Number Publication Date
HRP20110045T1 true HRP20110045T1 (hr) 2011-02-28

Family

ID=38324102

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110045T HRP20110045T1 (hr) 2006-04-13 2007-04-11 Sinteza acilaminoalkenilen amida korisnih kao antagonista supstance p

Country Status (28)

Country Link
US (2) US8008479B2 (enExample)
EP (1) EP2010498B1 (enExample)
JP (1) JP5208917B2 (enExample)
KR (1) KR20080108291A (enExample)
AR (1) AR060506A1 (enExample)
AT (1) ATE486853T1 (enExample)
AU (1) AU2007237482B2 (enExample)
CA (1) CA2645362C (enExample)
CL (1) CL2007001040A1 (enExample)
CY (1) CY1111294T1 (enExample)
DE (1) DE602007010269D1 (enExample)
DK (1) DK2010498T3 (enExample)
EC (1) ECSP088820A (enExample)
GT (1) GT200800209A (enExample)
HR (1) HRP20110045T1 (enExample)
JO (1) JO2630B1 (enExample)
MA (1) MA30394B1 (enExample)
MX (1) MX2008013117A (enExample)
MY (1) MY145069A (enExample)
NO (1) NO20084783L (enExample)
NZ (1) NZ571142A (enExample)
PE (1) PE20071223A1 (enExample)
PL (1) PL2010498T3 (enExample)
PT (1) PT2010498E (enExample)
RU (1) RU2433122C2 (enExample)
SI (1) SI2010498T1 (enExample)
TW (1) TW200815358A (enExample)
WO (1) WO2007118651A1 (enExample)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790699B2 (en) 2004-10-12 2010-09-07 Fmc Biopolymer As Self-gelling alginate systems and uses thereof
CN101273024A (zh) 2005-07-29 2008-09-24 康瑟特制药公司 新颖苯并[d][1,3]-二氧杂环戊烯衍生物
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
WO2008088727A2 (en) 2007-01-12 2008-07-24 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8080549B2 (en) 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US8013007B2 (en) 2007-02-26 2011-09-06 Concert Pharmaceuticals, Inc. Alpha 1A-adrenoceptor antagonists
WO2008109175A1 (en) 2007-03-07 2008-09-12 Concert Pharmaceuticals, Inc. Deuterated piperazine derivatives as anti-anginal compounds
CA2681628C (en) 2007-03-16 2016-10-18 Concert Pharmaceuticals, Inc. Inhibitors of cholesterol ester transfer protein
US8198305B2 (en) 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
US8349817B2 (en) 2007-04-25 2013-01-08 Concert Pharmaceuticals, Inc. Analogues of cilostazol
ES2401914T3 (es) 2007-04-25 2013-04-25 Concert Pharmaceuticals Inc. Análogos de Cilostazol
DK2792662T3 (da) 2007-05-01 2016-07-25 Concert Pharmaceuticals Inc Morphinanforbindelser
MX370608B (es) 2007-05-01 2019-12-18 Concert Pharmaceuticals Inc Compuestos de morfinano.
WO2008141021A1 (en) 2007-05-08 2008-11-20 Concert Pharmaceuticals, Inc. Deuterated derivatives of tetrahydrotriazolopyrazine compounds and their use as dpp-iv inhibitors
MX2009013565A (es) 2007-06-12 2010-06-02 Concert Pharmaceuticals Inc Derivados de azapeptidos.
US7687509B2 (en) 2007-07-09 2010-03-30 Concert Pharmaceuticals Inc. Pyrimidinecarboxamide derivatives
JP5389028B2 (ja) 2007-08-14 2014-01-15 コンサート ファーマシューティカルズ インコーポレイテッド 置換オキサゾリジノン誘導体
JP2010537717A (ja) 2007-08-28 2010-12-09 エフ エム シー コーポレーション 遅効性自己ゲル化アルギネートシステムおよびその用途
MX2010002679A (es) 2007-09-12 2010-03-29 Concert Pharmaceuticals Inc Derivados de 4-oxoquinolina deuterados para el tratamiento de la infeccion por el virus de inmunodeficiencia humana.
JP5647519B2 (ja) 2007-09-13 2014-12-24 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化カテコールおよびベンゾ[d][1,3]ジオキソールおよびその誘導体の合成
EP2212298B1 (en) 2007-10-18 2013-03-27 Concert Pharmaceuticals Inc. Deuterated etravirine
US8592487B2 (en) 2007-10-26 2013-11-26 Concert Pharmaceuticals, Inc. Deuterated darunavir
US8084464B2 (en) 2007-12-18 2011-12-27 Concert Pharmaceuticals, Inc. Tetrahydroisoquinoline derivatives
US8609673B2 (en) 2008-01-22 2013-12-17 Concert Pharmaceuticals, Inc. Vandetanib derivatives
US7855204B2 (en) 2008-01-22 2010-12-21 Concert Pharmaceuticals Inc. Derivatives of gefitinib
KR20100121527A (ko) 2008-02-29 2010-11-17 콘서트 파마슈티컬즈, 인크. 치환된 잔틴 유도체
WO2009128947A1 (en) 2008-04-17 2009-10-22 Concert Pharmaceuticals, Inc. Piperazine derivatives
WO2009154754A2 (en) 2008-06-17 2009-12-23 Concert Pharmaceuticals, Inc. Synthesis of deuterated morpholine derivatives
HRP20140195T1 (hr) 2008-08-29 2014-04-11 Concert Pharmaceuticals Inc. Supstituirani derivati triazolopiridazina
EP2334621A1 (en) 2008-09-16 2011-06-22 Concert Pharmaceuticals, Inc. Deuterated 2-amino-3-hydroxypropanoic acid derivatives
JP5730769B2 (ja) 2008-09-19 2015-06-10 コンサート ファーマシューティカルズ インコーポレイテッド モルヒナン化合物
US9045453B2 (en) 2008-11-14 2015-06-02 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
EP2400953A1 (en) * 2009-02-24 2012-01-04 Novartis AG Uses of nk receptor antagonists
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
DE102009001446A1 (de) 2009-03-10 2010-09-23 Evonik Rohmax Additives Gmbh Verwendung von Kammpolymeren als Antifatigue-Additive
WO2010107791A2 (en) 2009-03-17 2010-09-23 Concert Pharmaceuticals, Inc. Pyrazinoisoquinoline compounds
WO2010108103A1 (en) * 2009-03-19 2010-09-23 Concert Pharmaceuticals, Inc. Azepan-2-one derivatives
CA2759251C (en) 2009-04-23 2017-01-03 Concert Pharmaceuticals, Inc. 4-hydroxybutyric acid analogs
WO2010135579A1 (en) 2009-05-22 2010-11-25 Concert Pharmaceuticals, Inc. Fluorinated diaryl urea derivatives
CA2765015C (en) 2009-06-18 2020-05-05 Concert Pharmaceuticals, Inc. Deuterated isoindoline-1,3-dione derivatives as pde4 and tnf-alpha inhibitors
EP2454259A1 (en) 2009-06-23 2012-05-23 Concert Pharmaceuticals Inc. Deuterium-modified triazolo-pyridazine derivatives as gaba-a receptor modulators
US8557815B2 (en) 2009-08-14 2013-10-15 Concert Pharmaceuticals, Inc. Substituted triazolophthalazine derivatives
CA2771331A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
WO2011028820A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
US8278460B2 (en) 2009-10-15 2012-10-02 Concert Pharmaceuticals, Inc. Substituted benzimidazoles
WO2011063001A1 (en) 2009-11-18 2011-05-26 Concert Pharmaceuticals, Inc. Niacin prodrugs and deuterated versions thereof
DE102010001040A1 (de) 2010-01-20 2011-07-21 Evonik RohMax Additives GmbH, 64293 (Meth)acrylat-Polymere zur Verbesserung des Viskositätsindexes
EP3144296A1 (en) 2010-03-02 2017-03-22 Concert Pharmaceuticals, Inc. Deuterated tetrahydronaphthalene derivatives
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
US9226801B2 (en) * 2010-03-08 2016-01-05 Ibur, Llc Custom linkable imaging and multifunctional tray
US8575221B2 (en) 2010-03-17 2013-11-05 Concert Pharmaceuticals, Inc. Derivatives of dimethylcurcumin
US9107922B2 (en) 2010-07-16 2015-08-18 Concert Pharmaceuticals, Inc. Pyrimidinecarboxamide derivatives
US9074233B2 (en) 2010-09-01 2015-07-07 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
WO2012031072A1 (en) 2010-09-01 2012-03-08 Concert Pharmaceuticals, Inc. Process for preparing an enantiomerically enriched, deuterated secondary alcohol from a corresponding ketone without reducing deuterium incorporation
BR112013020620A2 (pt) 2011-02-14 2016-10-04 Concert Pharmaceuticals Inc análogos de ácido 4-hidroxibutírico
US9145390B2 (en) 2011-03-03 2015-09-29 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds
WO2012122028A2 (en) 2011-03-04 2012-09-13 Concert Pharmaceuticals Inc. Pyrazinoisoquinoline compounds
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
CN104364255A (zh) 2012-04-13 2015-02-18 康塞特医药品有限公司 取代的黄嘌呤衍生物
EP2838879A1 (en) 2012-04-20 2015-02-25 Concert Pharmaceuticals Inc. Deuterated rigosertib
EP3450434B1 (en) 2012-06-15 2021-02-24 CoNCERT Pharmaceuticals, Inc. Deuterated derivatives of ruxolitinib
WO2014008417A1 (en) 2012-07-04 2014-01-09 Concert Pharmaceuticals, Inc. Deuterated vercirnon
CA2908929C (en) 2012-07-12 2021-01-26 Concert Pharmaceuticals, Inc. Deuterated idebenone
CA2879400A1 (en) 2012-07-30 2014-02-06 Concert Pharmaceuticals, Inc. Deuterated ibrutinib
BR112015003153A2 (pt) 2012-08-17 2017-07-04 Concert Pharmaceuticals Inc baricitinib deuterado
EP2922838B1 (en) 2012-10-22 2018-03-14 Concert Pharmaceuticals Inc. Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione} .
MX2015008829A (es) 2013-01-09 2016-04-25 Concert Pharmaceuticals Inc Momelotinib deuterado.
WO2014150043A1 (en) 2013-03-15 2014-09-25 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9676790B2 (en) 2013-08-30 2017-06-13 Concert Pharmaceuticals, Inc. Substituted thienotriazolodiazapines
WO2015120393A1 (en) 2014-02-10 2015-08-13 Concert Pharmaceuticals, Inc. Substituted triazolobenzodiazepines
US10160778B2 (en) 2014-10-27 2018-12-25 Concert Pharmaceuticals, Inc. Pyrimidine phosphonic acid esters
US10196384B2 (en) 2015-03-31 2019-02-05 Vertex Pharmaceuticals (Europe) Limited Deuterated CFTR modulators
WO2016176335A1 (en) 2015-04-27 2016-11-03 Concert Pharmaceuticals, Inc. Deuterated otx-015
HK1258473A1 (zh) 2015-09-25 2019-11-15 Vertex Pharmaceuticals (Europe) Limited 氘代cftr增效剂
EP3377179B1 (en) 2015-11-19 2021-04-07 Concert Pharmaceuticals Inc. Deuterated epi-743
US10442761B2 (en) 2016-02-16 2019-10-15 Concert Pharmaceuticals, Inc. Deuterated GFT-505
CA3082834A1 (en) 2017-11-22 2019-05-31 Concert Pharmaceuticals, Inc. Deuterated analogs of d-serine and uses thereof
WO2019109021A1 (en) 2017-12-01 2019-06-06 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
WO2020206367A1 (en) 2019-04-03 2020-10-08 Concert Pharmaceuticals, Inc. Processes for the preparation of deuterated d-serine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69602087T2 (de) 1995-02-22 1999-09-09 Novartis Ag 1-aryl-2-acylamino-ethan-verbindungen und ihre verwendung als neurokinin- insbesondere als neurokinin-1-antagonisten
MY132550A (en) * 1996-08-22 2007-10-31 Novartis Ag Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
GB0010958D0 (en) * 2000-05-05 2000-06-28 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
KR20080108291A (ko) 2008-12-12
HK1125640A1 (en) 2009-08-14
ECSP088820A (es) 2008-11-27
DE602007010269D1 (de) 2010-12-16
WO2007118651A1 (en) 2007-10-25
US20110282053A1 (en) 2011-11-17
CA2645362A1 (en) 2007-10-25
US20090137797A1 (en) 2009-05-28
RU2008145102A (ru) 2010-05-27
PT2010498E (pt) 2011-02-08
GT200800209A (es) 2008-12-15
CL2007001040A1 (es) 2008-03-14
AR060506A1 (es) 2008-06-25
PL2010498T3 (pl) 2011-04-29
CY1111294T1 (el) 2015-08-05
JP2009533369A (ja) 2009-09-17
JP5208917B2 (ja) 2013-06-12
RU2433122C2 (ru) 2011-11-10
EP2010498A1 (en) 2009-01-07
DK2010498T3 (da) 2011-02-14
NO20084783L (no) 2008-11-12
CA2645362C (en) 2013-07-16
AU2007237482A1 (en) 2007-10-25
ATE486853T1 (de) 2010-11-15
TW200815358A (en) 2008-04-01
US8008479B2 (en) 2011-08-30
JO2630B1 (en) 2012-06-17
PE20071223A1 (es) 2008-01-22
NZ571142A (en) 2011-02-25
AU2007237482B2 (en) 2011-03-17
MX2008013117A (es) 2008-10-21
MY145069A (en) 2011-12-15
SI2010498T1 (sl) 2011-03-31
EP2010498B1 (en) 2010-11-03
MA30394B1 (fr) 2009-05-04

Similar Documents

Publication Publication Date Title
RU2008145102A (ru) Синтез ациламиноалкениленамидов, пригодных в качестве антагонистов вещества р
JP2009533369A5 (enExample)
GEP20074138B (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
HRP20090151T3 (en) Indozolone derivatives as 11b-hsd1 inhibitors
HUP0401538A2 (hu) Új, helyettesített aminometilcsoportot tartalmazó N-(arilszulfonil)-béta-aminosav-származékok, előállításukra alkalmas eljárás és a vegyületeket tartalmazó gyógyászati készítmények
ATE374765T1 (de) Substituierte heterocyclische amide
SK109095A3 (en) Method of production of trans-6-£2-(substituted-pyrol-1-yl)alkyl| pyran-2-one intermediates of this method and pharmaceutical agents
EA200900817A1 (ru) Способ получения фторметилзамещённых гетероциклических соединений
GEP20074135B (en) Process for the synthesis of (is)-4,5-dimethoxy-1-(methylaminomethyl)- benzocyclobutane and addition salts thereof, and to the application thereof in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
CA2401832A1 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
BRPI0507005A (pt) compostos, composições farmacêuticas, uso de um composto, e, método de preparo de uma composição farmacêutica
MX2009005440A (es) Procedimiento para la produccion de derivados de fenilalanina que tienen estructuras de base de quinazolinodiona e intermediarios para la produccion.
WO2004020430A3 (fr) Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
NO20052476L (no) 2-alkyl-(2-amino-3-aryl-propionyl)-piperazinderivater og beslektede forbindelser som melanokortinreseptorligander for behandlingen av obesitet.
MY136686A (en) Salt forms of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide and method of production
TNSN07006A1 (en) Novel heterocyclic compounds
HRP20030566B1 (en) Improved process for carbapenem synthesis
ATE429429T1 (de) Pharmazeutisches verfahren und damit hergestellte verbindungen
HRP20090474T1 (hr) Postupak i intermedijeri za sintezu kaspofungina
NO20063681L (no) Aryloksyalkylkarbamattype derivater, fremgangsmate for fremstilling derav og anvendelse av derivatene i terapeutiske midler
TW200606167A (en) Method for preparation of 1-oxachephalosporin-7 α-methoxy-3-cloromethyl derivative
CA2461060A1 (en) Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof
NO20071253L (no) Fremgangsmate for syntese av C-2, C-3 substituerte N-alkylerte indoler anvendbare som CPLA2-inhibitorer.
JP2011510026A5 (enExample)
ATE550326T1 (de) Als modulatoren von hdl einsetzbare verbindungen